Persistent systemic inflammation in chronic critical illness

Respiratory Care

Volumn 57, Issue 6, 2012, Pages 859-864

  Cox, Christopher E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic critical illness; Inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ARTICLE; CHRONIC CRITICAL ILLNESS; CHRONIC INFLAMMATION; CLINICAL FEATURE; CRITICAL ILLNESS; DISEASE ASSOCIATION; HUMAN; MUSCLE WEAKNESS; OUTCOME ASSESSMENT; PATIENT CARE; PROGNOSIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT PLANNING; CHRONIC DISEASE; COMORBIDITY; INFLAMMATION; MITOCHONDRION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SURVIVOR;

BIOLOGICAL MARKERS; CHRONIC DISEASE; COMORBIDITY; CRITICAL ILLNESS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MITOCHONDRIA; MUSCLE WEAKNESS; OXIDATIVE STRESS; PROGNOSIS; RISK FACTORS; SURVIVORS;

EID: 84863570751     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.01719     Document Type: Article

References (47)

1. Carson SS, Bach PB. The epidemiology and costs of chronic critical illness. Crit Care Clin 2002;18(3):461-476.
2. Nelson JE, Cox CE, Hope AA, Carson SS. Chronic critical illness. Am J Respir Crit Care Med 2010;182(4):446-454.
3. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 1999;282(1):54-61.
4. Marik PE. Critical illness-related corticosteroid insufficiency. Chest 2009;135(1):181-193.
5. Russell JA. Management of sepsis. N Engl J Med 2006;355(16): 1699-1713.
6. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348(2):138-150.
7. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345(19):1359-1367.
8. Leijten FS, Harinck-de Weerd JE, Poortvliet DC, de Weerd AW. The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation. JAMA 1995;274(15):1221-1225.
9. Garnacho-Montero J, Madrazo-Osuna J, Garcia-Garmendia JL, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar A, et al. Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med 2001;27(8):1288-1296.
10. Tepper M, Rakic S, Haas JA, Woittiez AJ. Incidence and onset of critical illness polyneuropathy in patients with septic shock. Neth J Med 2000;56(6):211-214.
11. Coakley JH, Nagendran K, Honavar M, Hinds CJ. Preliminary observations on the neuromuscular abnormalities in patients with organ failure and sepsis. Intensive Care Med 1993;19(6):323-328.
12. De Jonghe B, Sharshar T, Lefaucheur JP, Authier FJ, Durand-Zaleski I, Boussarsar M, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002;288(22):2859-2867.
13. Hough CL, Steinberg KP, Taylor Thompson B, Rubenfeld GD, Hudson LD. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med 2009;35(1):63-68.
14. Levine S, Nguyen T, Taylor N, Friscia ME, Budak MT, Rothenberg P, et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med 2008;358(13):1327-1335.
15. Jaber S, Petrof BJ, Jung B, Chanques G, Berthet JP, Rabuel C, et al. Rapidly progressive diaphragmatic weakness and injury during mechanical ventilation in humans. Am J Respir Crit Care Med 2011; 183(3):364-371.
16. de Letter MA, Schmitz PI, Visser LH, Verheul FA, Schellens RL, Op de Coul DA, et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001; 29(12):2281-2286.
17. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002;360(9328):219-223.
18. Di Giovanni S, Molon A, Broccolini A, Melcon G, Mirabella M, Hoffman EP, et al. Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol 2004;55(2):195-206.
19. Showalter CJ, Engel AG. Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve 1997;20(3):316-322.
20. Tiao G, Hobler S, Wang JJ, Meyer TA, Luchette FA, Fischer JE, et al. Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest 1997;99(2):163-168.
21. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996;335(25): 1897-1905.
22. Fenzi F, Latronico N, Refatti N, Rizzuto N. Enhanced expression of E-selectin on the vascular endothelium of peripheral nerve in critically ill patients with neuromuscular disorders. Acta Neuropathol 2003;106(1):75-82.
23. Latronico N, Peli E, Botteri M. Critical illness myopathy and neuropathy. Curr Opin Crit Care 2005;11(2):126-132.
24. Druschky A, Herkert M, Radespiel-Troger M, Druschky K, Hund E, Becker CM, et al. Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med 2001;27(4):686-693.
25. Katz JN, Kolappa KP, Becker RC. Beyond thrombosis: the versatile platelet in critical illness. Chest 2011;139(3):658-668.
26. Carson SS, Cox CE, Holmes GM, Howard A, Carey TS. The changing epidemiology of mechanical ventilation: a population-based study. J Intensive Care Med 2006;21(3):173-182.
27. Claeys R, Vinken S, Spapen H, ver Elst K, Decochez K, Huyghens L, et al. Plasma procalcitonin and C-reactive protein in acute septic shock: clinical and biological correlates. Crit Care Med 2002;30(4): 757-762.
28. Povoa P, Almeida E, Moreira P, Fernandes A, Mealha R, Aragao A, et al. C-reactive protein as an indicator of sepsis. Intensive Care Med 1998;24(10):1052-1056.
29. Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003;123(6):2043-2049.
30. Silvestre J, Povoa P, Coelho L, Almeida E, Moreira P, Fernandes A, et al. Is C-reactive protein a good prognostic marker in septic patients? Intensive Care Med 2009;35(5):909-913.
31. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMCInfect Dis 2007; 7:10.
32. Pettila V, Hynninen M, Takkunen O, Kuusela P, Valtonen M. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 2002;28(9):1220-1225.
33. Povoa P. C-reactive protein: a valuable marker of sepsis. Intensive Care Med 2002;28(3):235-243.
34. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003;31(6):1737-1741.
35. Aouifi A, Piriou V, Bastien O, Blanc P, Bouvier H, Evans R, et al. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients. Crit Care Med 2000;28(9):3171-3176.
36. Icard P, Fleury JP, Regnard JF, Libert JM, Magdeleinat P, Gharbi N, et al. Utility of C-reactive protein measurements for empyema diagnosis after pneumonectomy. Ann Thorac Surg 1994;57(4):933-936.
37. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7(3):210-217.
38. Rowther FB, Rodrigues CS, Deshmukh MS, Kapadia FN, Hegde A, Mehta AP, et al. Prospective comparison of eubacterial PCR and measurement of procalcitonin levels with blood culture for diagnosing septicemia in intensive care unit patients. J Clin Microbiol 2009; 47(9):2964-2969.
39. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302(10):1059-1066.
40. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011;39(9): 2048-2058.
41. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006;34(10):2596-2602.
42. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007;167(15):1655-1663.
43. Powers SK, Hudson MB, Nelson WB, Talbert EE, Min K, Szeto HH, et al. Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm weakness. Crit Care Med 2011;39(7): 1749-1759.
44. Schweickert WD, Hall J. ICU-acquired weakness. Chest 2007;131(5): 1541-1549.
45. Winkelman C. Inactivity and inflammation in the critically ill patient. Crit Care Clin 2007;23(1):21-34.
46. Winkelman C, Higgins PA, Chen YJ, Levine AD. Cytokines in chronically critically ill patients after activity and rest. Biol Res Nurs 2007;8(4):261-271.
47. Micheel CM, Ball JR. Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington, DC: Institute of Medicine/ National Academies Press; 2010. http://www.nap.edu/openbook.php? isbn_0309151295.